The technology is based on a novel target, the S100A9 protein which plays a critical role in turning acute inflammation into a chronic state. The S100A9 protein acts as an amplifier of leukocyte migration during inflammation. It is also a potent inducer of pro-inflammatory cytokine production like TNFα, IL-1β, and IL-6. As such, S100A9 represents a very promising new therapeutic target for the control of inflammation. Anti-S100A9 antibodies have been developed and have been shown to be as efficacious as anti-TNF in mouse models of Crohn's disease and rheumatoid arthritis.